Sign in

    Martin Auster

    Senior Equity Analyst at Raymond James

    Martin Auster is a Senior Equity Analyst at Raymond James, specializing in general sector research and covering a broad portfolio of approximately 50 stocks, including prominent biotechnology and healthcare companies. With a 4.40-star rating and a 50% success rate according to TipRanks, he is recognized for his balanced and consistent performance in stock recommendations across a diverse set of firms. Auster began his career in finance in 2002 and has been actively engaged in equity research for over two decades, amassing strong institutional relationships and deep sector expertise. He is registered with FINRA and holds requisite securities licenses, underpinning his professional credentials in financial analysis and advisory.

    Martin Auster's questions to Wave Life Sciences (WVE) leadership

    Martin Auster's questions to Wave Life Sciences (WVE) leadership • Q2 2025

    Question

    Martin Auster of Raymond James followed up on the WVE-007 program, asking if Activin E reduction data from cohort two would influence the size of cohort three and whether that could potentially shift the planned Q1 2026 data disclosure timeline for cohort three.

    Answer

    President & CEO Paul Bolno stated that they would expect a similar approach for cohort three as they took for cohort two, but this would not shift the timeline for delivering the 400 mg cohort data in 2026. He emphasized the study was well-designed to assess the dose response between 240 mg and 400 mg and that recruitment has been incredibly efficient, keeping all data readouts on track.

    Ask Fintool Equity Research AI